🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: 62.5mcg

Found 16 matching trials

Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg

PHASE3

The purpose of this study is to evaluate the lung function response to UMEC...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-10

Trial ID

NCT01716520

Treatments Being Tested

Umeclidinium/Vilanterol 62.5/25 mcg Umeclidinium 62.5 mcg Vilanterol 25 mcg

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This is a multicenter, randomized, double-blind, placebo-controlled, 2-peri...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-01-23

Trial ID

NCT02275052

Treatments Being Tested

UMEC/VI DPI Placebo DPI Albuterol/salbutamol MDI

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01328444

Treatments Being Tested

GSK 573719 +GW642444 125/25 GSK573719 + GW642444 62.5/25 GSK 573719 125 GSK 573719 62.5 GW642444 25 Plb

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

PHASE3

After screening, subjects will enter a 4 week open-label run-in period with...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-10

Trial ID

NCT02119286

Treatments Being Tested

FF VI UMEC Placebo

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-16

Trial ID

NCT01323660

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GSK573719 125 GSK573719 62.5 GW642444 25 placebo

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

PHASE2

The study will evaluate the dose response, safety, and pharmacokinetics of ...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-09-01

Trial ID

NCT00950807

Treatments Being Tested

Tiotropium Placebo GSK573179

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01313650

Treatments Being Tested

62.5/25mcg 62.5mcg 25mcg Placebo

Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)

PHASE4

Atrial fibrillation is a common heart rhythm disturbance, causing important...

Status

Completed

Location

City Hospital

Start Date

2016-12-20

Trial ID

NCT02391337

Treatments Being Tested

Bisoprolol Digoxin

Air Pollution and Inhaled Corticosteroids in COPD

PHASE4

Studies have shown that people with chronic obstructive pulmonary disease (...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2025-04-01

Trial ID

NCT06552364

Treatments Being Tested

LABA+LAMA LABA+LAMA+ICS Filtered Air Diesel Exhaust

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

PHASE2

This is a multi-national, randomized, double-blind, 3-period crossover, inc...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-05

Trial ID

NCT01641692

Treatments Being Tested

GSK573719 Active treatment or Placebo GSK573719 (Sub-group cohort)Salbutamol/Albuterol

Previous Next